Scandonest Plain en es it fr

Scandonest Plain Brand names, Scandonest Plain Analogs

Scandonest Plain Brand Names Mixture

  • No information avaliable

Scandonest Plain Chemical_Formula


Scandonest Plain RX_link

Scandonest Plain fda sheet

Scandonest_Plain FDA

Scandonest Plain msds (material safety sheet)

Scandonest_Plain MSDS

Scandonest Plain Synthesis Reference

No information avaliable

Scandonest Plain Molecular Weight

129.164 g/mol

Scandonest Plain Melting Point

223-226 oC

Scandonest Plain H2O Solubility

Freely soluble as HCl salt

Scandonest Plain State


Scandonest Plain LogP


Scandonest Plain Dosage Forms

Extended release tablet (500 mg or 1000 mg)

Scandonest Plain Indication

For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.

Scandonest Plain Pharmacology

Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

Scandonest Plain Absorption

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.

Scandonest Plain side effects and Toxicity

Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

Scandonest Plain Patient Information

Scandonest Plain Organisms Affected

Humans and other mammals